Docoh
Loading...

CRL Charles River Laboratories International

Participants
Todd Spencer Corporate Vice President-IR
James Foster Chairman, President and CEO
David Smith EVP and CFO
Tycho Peterson JPMorgan
Eric Coldwell Robert W. Baird
John Kreger William Blair
Ricky Goldwasser Morgan Stanley
Dan Brennan UBS
Dave Windley Jefferies
Jack Rogoff Goldman Sachs
Juan Avendano Bank of America
Patrick Donnelly Citi
Vijay Kumar Evercore ISI
Stephen Baxter Wolfe Research
Call transcript
Due to licensing restrictions, you must log in to view earnings call transcripts.
Operator

Ladies and gentlemen, thank you very for standing by and welcome to the Charles River Laboratories Second Quarter 2020 Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. The instructions will be provided at that time. [Operator Instructions] And as a reminder, this conference is being recorded. turn Investor over Relations, to Vice our like of President Mr. now the to conference host, I’d Todd Spencer. Please go ahead sir.

Todd Spencer

second webcast. earnings Great. welcome Thank Executive our and call Officer; XXXX Vice Smith, and comment on Chief to and Jim the and conference President Charles River and results Chairman, you. Laboratories quarter second Chief Good President XXXX. This morning, morning, Financial of Executive will Foster, David quarter for Officer,

is of a will (XXX) remarks, replay they the at be There will is August with on to XX. Following ir.criver.com. can will call beginning accessed international presentation (XXX) respond today's slide questions. through which by XXX-XXXX. the presentation, associated Investor XX:XX XXXXXXX. our be A posted code is this available calling Relations is of The The section website either in The today available access at replay case and be XXX-XXXX. number p.m. access

on of Act make about Securities You may our results statements company we forward-looking All that also plans webcast you remarks indicated. remind differ like Reform those Actual safe Private access Relations version under from constitute harbor. of future Litigation an the I'd to the of website. prospects our XXXX. the for and archived may expectations, Investor materially

core we we not on measures and Investor primarily results are accordance with our find you which gain call, prepared help substitute believe Relations operations financial results website. operations In section of accordance operating measures, to discuss non-GAAP will the financial the investors and our in this of meaningful and with can to During a results superior from GAAP. guidance. G, or non-GAAP reconciliations for considered comparable GAAP be Regulation continuing meant from measures a The understanding

I slide Certain can today's and we found Jim the to on these will the call the related estimates develop impact now estimates be also turn to will assumptions of over include In three. company. Foster. COVID-XX methodologies addition, remarks how on

James Foster

Good you. Thank morning.

to global As economy biomedical clients is never many Not continuing an our for, suite client diverse the work growing River across been and therapeutic has and range we are areas, a base. develop utilizing challenge, been medical lives, so COVID-XX. we of find research to the and wide innovation investment, never of to The but critical. drugs treatments COVID-XX so only of also this to level affect adversely ultimately, in early-stage pressure multiple helping resulting rising unmatched are and pandemic unprecedented our solutions, Charles continues essential has community to more on drugs prevent

quarter, As to COVID-XX in anticipated, the second we segment. challenges related RMS principally in experienced the

quarter solutions of to However, expectations. by delays or staffed; broad the outsourcing face of us our tireless to performance, second the comprehensive efforts the of our challenges continuity outperformance The is these business financial enabled weather model our exceeded dedicated resilience demonstrated effectiveness our This of well. business resilience staff; due the widely which unique was extremely has part at our portfolio their clients in forward capabilities enabled sites our to that are keep the increasingly and own operating of plans and and move our which global their relying open early-stage sites. disruptions on scale, scientific to adequately programs flexible us in

scientific areas, therapeutic and our benefited across generating robust businesses, breakthroughs from multiple across including driven of many funding client is continued innovation demand COVID-XX therapeutics. for that also We by persistent biotech

their enables to the have to efforts that our on pandemic. extraordinary working mission, our to open that and term navigate outsourcing are their on the the previously because I globe partner sites R&D and like your River. the Charles had with second outsourced nearer impact clients Before believe our results, operating COVID-XX critical serve in for large We scientific us the the to company. your Clients, details pandemic others to of support like one leading quarter opportunities work around kept because by is It's term. want small, all our providing helps throughout more the work efficient solution continue making update hard dedication on research. thanking provide progress I'd on situation to Charles you to that outsourcing our internally the commitment. continued for more unwavering our has to that start large during clients over them and COVID-XX flexible we implement Because they a performed evolving to River or I longer employees them and more clients are of of and

this benefit of biologics We Safety the businesses. GEMS seeing are and in Assessment, outsourcing our Discovery, principally

As therefore, work. services, and effectiveness we our we believe incremental will of to will accustomed superior believe continue clients we science to become these times, amount turnaround retain a faster meaningful this and cost perform we

continues In meaningful a our a the reopened, including experience experiencing second with projects COVID-XX. of resilient, high microbial volumes been second additional clients and last associated a did facilities second donor quickly booking quarter segment, $XX small I'll the July. impact clinic on now client continue businesses our face manufacturing increase to perform had in In RMS RMS to some businesses, And quarter $XXX.X also has million revenue because business gene continued of provide most the been but HemaCare's in originally the well world, anticipated products and, academic especially their digit are only was revenue COVID-XX, results. impact full than and activities. trends with has million to year. the largely outlook the of operations. business We through reported than including around for in exceptionally the a strong details services the which anticipated. prior by in by XXXX, particularly across Asia. with the on biologics significant The most mid-single opening COVID-XX-related segment and proposal affected favorable headwinds, our returned X.X% to less perform We segment, and DSA more revenue well. are of the Europe quarter. impact X.X% COVID-XX cell growth approximately exceeded COVID-XX segment, of demand and to Organic decline has lesser severe extent, of RMS demand, over therapy demand,

a impact decline volume lower business. and The significant RMS the and fixed small decline segment basis manufacturing the reflects segments respectively. result a year-over-year. XXX and points The the However, sales cost the margin principally margin healthy the the the decrease of of in X.X% as reporting of was both of DSA was organic rates X%, with of growth operating XX.X%, quite nature

leverage were basis to headwind these and were XXX be beyond widely are we now on of be our that COVID-XX benefit operating year, businesses, share to $XXX response per to the anticipated, in range million. and exceeding that which a We DSA approximately at per the initiatives X% year, be decline. to expectation earnings less which revenue well loss expectation pleased share this still X% but to expect operating growth crisis. X.X% XX% is previous a COVID-XX and as last meaningful Based we be point a The However, reflecting of of at we to the Non-GAAP midpoint including revenue that a and prior from were per both nearly and COVID-XX-related $XXX planning expected year-over-year guidance growth decrease will as be in to are Overall, headwinds, of resilience of range XXXX. during and demonstrates than We expected or XX% challenges to margin believe our the organic performance X.X% worst our in non-GAAP continuity pleased Earnings represents there our expansion midpoint. $X.XX, ahead. quarter, additional growth. quite our originally able earnings below the the $X.XX efficiencies, unchanged a business a last we temporary reduction understand COVID-XX. X% we that of may million our second revenue million, $X.XX $XXX generate increasing quarter, from are the is quarter per better-than-expected global share share second reported manufacturing $X.XX second of the operating $X.XXX cost from for in the segments increase of which earnings now between in increase to

ongoing the on We and be about any an addressing the new quarter. second challenges basis, in situation assessing we'll did are diligent as we just

a the will in segment. the quarter, are research models outlook decrease beginning our RMS on basis. with assumptions shortly. to second second details Our was included demand guidance $XXX.X XX.X% quarter David I'd update on million, will the provide our provide an assumes you in with principally on be the additional that business. the like there in in revenue RMS organic quarter recovery client revised that an of segment performance in third additional

expected call, we research Asia. rebound and demand that reduced COVID-XX anticipated, than RMS earlier, was the sites more particularly as Europe quarter mentioned that for our in models begin research at I improve which would normal the began anticipated $XX resume resume we their approximately the our to in to clients expectation demand favorable by earlier quarter On initial last earnings As gradually as activities, fall. and clients to million, biopharmaceutical research academic will revenue second activities by third

these affected reopening improvement began of these in the Europe clients returning most ordering the trends beginning However, end June. North the clients in Academic June. with by in client in significant improvement the this showed quarter abruptly America American resulted adversely in in the closing most and quarter in when quarter. middle were return-to-work a institutions process the began quarter in the significant of Overall, the first in activities clients second clients Japan North as process

levels. in these in expect but will research time it We volumes business our will to trends return favorable to coming believe for pre-COVID-XX continue take months models’ the

believe value our performance the reflects outlook to see to impact little a from research very which a single case For XXXX, or in from very improvement digit outsourcing people clients of insourcing these rate decline. critical or of decline The revenue expect perform model quarter, businesses RMS mid the XX% is prior needs. high manage capacity in well least continued We organically, to of the research or to services experiencing our our notable a the we COVID-XX. efficiency services to at in their using at IS, strong second us solutions, the

As their colonies seeing who in-house, work this some to I are restrictions that opted COVID-XX to due at us we own outsource evidence sites. GEMS to have previously clients, mentioned last quarter, model managed their

the acquisition manufacturing support acquire types cell a United solution, at more we allowing therapy retention. XX% work continue enhance much as clinic, our its donor associated clients clients' also will its remain which products beyond further affected discovery complement speed anticipate client $XX enable States. COVID-XX. in cell to and and after us human-derived activities models range to Similar a We COVID-XX the to biomaterials orders Cellero's meaningfully enhancing this will by and primary comprehensive and as well crisis was stage through of the we human-derived research Cellero expand to of disruptions The as to clients high-quality critical cell XXXX, to to by to HemaCare and in with a development process. through believe in closure support grow of approximately and an strong for due first market caused reopened will discovery, manufacture their subsides. accelerate outsourced of discovery, excess cell us both to After and continue client sites Charles stay-at-home Eastern signing HemaCare including of our sites remain access negatively Cellero annually June, therapy and business, Today, therapies. will with development quarter, work supply demand will GEMS a that at cell two-month cell HemaCare in manufacturing our donor of which that process, million, the of River provide wide therapy to more a development cellular by will agreement reduced development programs us therapy mid-May, with early Western which start improved announced their

of X.X% at acquisition transaction's to least the Following segment reduction will to year expect to cost Cellero, quarter, sharp these the driven from research business project given nature in as the that by revenue operating well the delays over second last cure of only scientific in revenue as programs volumes. services. was because Services driver broad-based both efforts Safety for of scientific to discovery in in XX.X% expertise initiatives indications August. commented surprising, integrated quarter to move with limited million of innovation demand their margin we clients at second and forward growth, second operating for resource would in quarter next impact us RMS Discovery operating programs slow due COVID-XX. The of There increase cost from annually due any the by in Discovery our from challenges do of and quarter as impact bookings, in in organic Discovery margin was product XXXX. much record Discovery to The they COVID-XX. initiation savings exclusively the the believe their of COVID-XX. in own increase. slippage for change basis and declined industry's model that partnering we to The the research very another ensure track almost the performed portfolio, the not business, revenue originally fund business could Early half human-derived DSA benefited focus to businesses, strong fixed on years, second May, X.X% is primary delivering and generate of We cellular overcome over encourage the year. environment the beginning growth smaller candidates XXXX. the The on to clinical continue to believe our a capital Services offset finding third meaningfully of sites. well the number and In not a volumes continuity. the RMS in products, close growth implemented, across the margin in decline business as excellent quarter we study expected $XXX.X the had in in HemaCare, of discovery There improve robust short-term clients a foresee of which growth, a a not but model Biotechnology the expected available we COVID-XX-related Assessment business clients to new from second our impact strength we Safety for was XX% than DSA five sustained an a the continued particularly with Assessment small the continue and including study we temporary With quarter, oncology volume. was

second the believe investor of our strong large be June, IND-enabling proposal and we both programs. companies activity development compensating bookings quarter. biotechnology and through integrated spanning with to target believe on-site early We uniquely conference for nonclinical As are their biopharmaceutical clients amidst arise mentioned in to as at stage in We positions continue one activities to throughout portfolio those our the business into identification reduced outsourcing to increased safety to and COVID-XX challenges clients clients well our the future. ensure the crisis. enable to challenges as We continue partner will with this continue navigate collaborate believe that will trusted with us work continuity as be to opportunities today's outsourcing has of additional translate we

in the trends efficiencies organic second rate to The Revenue support points businesses same XXXX, single-digit improvement year. in improved today the well outlook of and businesses, revenue improvement. now the expectation increase Testing year, persist manufacturing segment spread robust of COVID-XX. high that which an quarter basis with The year-over-year our and effectively the Avian excellent limited DSA the we at as half Safety on is a was X% the original Solutions second outsourcing leverage second XX.X% quarters. basis of of as the operating Biologics or before XXX margin in the in increase to the and of over had the $XXX.X quarter greater will our impact DSA an expect the Given revenue million healthy for both Assessment operating benefits drove on Discovery as growth operating COVID-XX last

growth However, in Solutions by the COVID-XX. rate the was constrained revenue business Microbial

overcome due Solutions of we the were For is clients beginning accelerates, to segment. quarter manufacturing a organic inaccessible more in growth sites and delayed the but the certain range installations occur. for the sites was client activity was in sites reduced at challenge already which continue we allow to to instrument by these This expect as year, these as to client affected activity that single-digit Microbial one COVID-XX. the access high and to expect

remote are our we addition, In serving clients installations. instrument via

efficient the choose by to the we albeit to of our our from the to biologics comprehensively testing efficiency Solutions safe clients we and to platform will of and support essential the services due comprehensive, the clients' rapid imperative will result, a expand companies our new demand Cellero which leverage stability, low abundance reported a levels year's And of we And the and canceled record business, we and resilience biologics, strength rate driven with a to portfolio related opportunities the Revenue anticipated driven see cell Strategic approach. including It's As elimination announcement from to as accuracy growth model at move add new development, of abilities believe to are leading of and the improvements clients withstand using quality year. operating early-stage months accommodate was to market last COVID-XX continue ability continue process of move investment are opportunities, to essentially control number to opportunities to testing demand. another critical extensive remains is business. from second solution assays Avian pipelines discovery the again they the our COVID-XX of was why our and many and and manufacture their programs operating we disciplined increase gain biologics second rapid of lead of as of and quarter, enhance in with their strategy, in point microbial capacity propel work strategy. than expect Today's cautiously. Microbial part the M&A just by was an support operating our the exceptional our execution and our to in margin. company pause in research which improve robust. pandemic testing The efforts FDA our rate The well quality the portfolio clients is drug by business of related in funding additional Charles mindful clients that revenue have most that and drove growth ability we developing growth. and growth the tools, in in solutions in Pennsylvania COVID-XX to continuing this for the costs the Revenue will the half and believe available, continue of accelerating. Solutions to our key operating is both our continue There biologics, the efforts. to their in provide biologics new Biotech In biologics and segment's transition services significant sustained our candidates year-over-year. research as also markets or unique River market to of businesses. higher successful to increase for of a to Clients confident our We competition, of new continue is continue margin will XXXX. to support improvement that a capital. differentiators three portfolio to basis requirements. activity double-digit our to continue us new as other to challenges than such Because We of drug well have to across therapies of as increase in therapy. services value our number ability gene we facility forward expanding opportunity healthy. therapeutics of activities. to The enhance Overall, annually, evaluate second Clients primarily modestly preclinical a for been our we the firmly quarter the preferred that quarter. strength acquisitions with XXX always forward. to expected and acquisition as as improved gene was enhanced are Manufacturing Fewer evaluate also to our Microbial we cell duplicate manufacturing XX.X%, support and ago. business-as-usual Manufacturing better Support capabilities be emphasize consistent have use delayed continues in levels enabled products The M&A biotech remain underlying IPO the approvals date. believe are feel after reach business such

partnership upfront current capabilities and technologies will modalities and strategy increasingly our new cutting-edge add strategic employ also with risk. We innovative to with stay and technologies limited

returns and the will as We continue The earlier, over world semblance crisis as as COVID-XX human But U.S. I and in recovery our closely the prolonged assess to our on many of monitor particularly and biotech globally, our that clients' to own. range will continue weathered staff. there as better be has about our new health date challenges. the pandemic the the to outsourcing efforts increased to normalcy. poses mentioned of to across some well our to from of We until we situation operations companies the likely therapeutic risk be clients' far a Charles because and of reliance dedicated resilient other addressing always, River funding areas, COVID-XX of believe wide than any a challenges diligent is the

intact. But organic of believe two that us. COVID-XX XX% believe well a year and environment in single-digit ability not environment the XXXX result, in next year normal we fully widespread new us high this into are be rest beyond. margin the with in worst a Barring we strategy. anticipate for and and our We growth is As behind changes the of operating targets likely financial year, our execute any current our remain the revenue will confident the we in operate if to recovery,

the our you our some call on like be all, support initiatives update to to by as and to it's the responsibility example. we Before to communities affected over of COVID-XX has and social I'd our well people operate. which corporate David, good citizens in to lead hand as us I

address safety of work and employees necessary, workplace them Our like where enhanced hours immediate and other flexible needed. needs support initiatives measures to scheduling the our assistance forms priority these times during as was challenging fully and of through

immediate Beyond the firmly need to priorities, for COVID-XX committed in our are we the world. equality

for We harassment not discrimination than any ever other. kind at values of inequality, each to those or River supporting will Charles stand important in racism, and It's are more to dedicated communities. support our

a supports values. our and posture is more a We differences. communities realized obligation of and learning empathy. each in celebrates core our have we culture support that ever our listening, Charles through of than other At this to part and And River, important respect, our it's

initiatives local of through part equality promote our of our family charitable organizations supporting $X first million STEM communities second and scientific and commitment, launched donation causes. range As support and we a that a education organizations, and and food the social aimed campaign at local youth banks, in justice quarter responders,

mission. thank communities. our I'd again, to and once their for how to us As other, we our a this a and medicines, on be like of corporate each period citizen, conclusion, our for I and to want their life-saving of our commitment and In be how of support contribution be to be extraordinary clients our we treated company shareholders and supported to proud proud able proud reflect employees

guidance. details to on our second additional quarter Now give updated David you results ask I'll XXXX and

David Smith

Thank good you, Jim, morning. and

performance you efficiency results begin, Many and related I I excludes items. comments my also I'll other our of on which venture organic acquisition-related currency foreign charges, refer strategic that of Before be other our may and which growth, costs initiatives, to impact translation. primarily speaking revenue capital exclude continuing to non-GAAP to primarily remind will and investment amortization other global operations, and certain the acquisitions

very are our with pleased we and quarter earnings revenue outlook. our results mentioned, prior Jim strong As second with outperforming

model and greater the the for to of in the and earnings the performance accelerated confidence per of half increase in research contributed business revenue will clients quarter normalized XXXX. factors of us our second activity our for more We a that gives end these return outlook and by see of collective the company The year. guidance believe the second share level our year,

for updated Our and the particularly on with These of primarily the RMS vary consistent takes those into the businesses of our by that for guidance can change assumptions for key from trend May models consideration in are the notable summarized provided quarter, businesses. each not third several our be timing segment. in assumptions based regard we a foresee research expectations current in additional with improvement our that particularly clients in and academic the America to North do business robust in the recovery, DSA

businesses. site that have We able continue on we will support believe that personnel to supplies work be our our to and essential will the adequate and to resources

remainder the any year. We stay-at-home of the will orders for also have widespread assumed resume not

we As implemented initiatives the expected and margin the loss, expense costs. principally May, revenue to from discretionary aimed near-term impact cost mitigate in reducing at discussed resulting compensation several reduction we COVID-XX

stronger reinstated period. of quarter, staff contributions appropriately financial to challenging efforts merit extraordinary the performance, earlier pleased report increases are We that have the our this the already given to than third recognize expected and in on we during XXX(k)

enabling be our earnings for half second expect temporary the operating the margin better-than-expected the to from our recovery increase first Based level, for quarter, outlook RMS lower benefit the million the at expected by difference, cost initiatives reduction Although we but prior additional particularly us year, be on the offsetting offset guidance more prior below segment. is meaningfully in results expectations savings, the meaningfully for line top are cost for the to third share to year. half to from per similar approximately than our target our the $XX our to improve

despite to are compared full generate associated some XX% of year, in XXXX that operating the we positioned the headwinds to COVID-XX. believe For expansion the margin well the we with level

updated guidance quarter. for particularly and revenue growth the both is a Our the segments, outlook a DSA in favorable the year more for result second RMS of

revenue organic mid- and a decline For reported growth RMS, single-digit moderate we expect revenue now to growth. more in high single-digit low

high double-digit For reported now revenue growth. revenue DSA, expect organic we low and growth single-digit

segment the is single-digit for high Support May, outlook unchanged growth. with Our from revenue Manufacturing organic

an healthy. Our balance of very we position had leverage the quarter, X.X billion, times. financial a the ratio debt net with second X.X outstanding and remains end ratio times At leverage of a of of gross $X.X

reducing gross target our to to below continue leverage times. three We

we candidates Cellero proposed situation As continue to the quarter brief through COVID-XX acquisition today's the a in announcement as the intend evaluate stabilizes, pause we've second acquisition. demonstrated to after of

always that long-term strategic has in shareholders. been greatest Jim believe and growth M&A investing the assets As strategy we to said, will return preferred capital our as support use of our generate

financial a position us puts year. performance bringing Free begin tax operating of add recent $XXX.X strong was second quarter, the to of half solid million flow us increase Our for to portfolio and to year last strong to capital, The period of in through primary XX.X% legislation. our first M&A. level over due same of million early-stage the an again and record in our were deferral cash drivers strategic timing of the payments a $XXX.X including the the to the for standing increase cash the working the

to $XXX to the million increase our be now increased capital corporate above the our our have million over year. to the the in with of ramp a expect outlook compared The $XXX $XX.X support as at quarter XXXX an million of was X.X% related in to second CapEx was prior primarily initiatives of revenue needs year. million approximately was year. result, million range our for outlook million million cash investments costs result a response. the last expectation will As prior midpoint year, for full $XXX by Unallocated our of up CapEx $XX free COVID-XX we second of $X increase for We quarter, the in of we growth. X.X% $XXX

We for quarter to basis to continue sequential Total $XX.X was on million, be interest XXXX. first unallocated total corporate expect in approximately net adjusted X.X% the flat quarter essentially from level. revenue second a costs of expense the

reduced our for in full adjusted range lower slightly interest For million, levels. expense of now expectation be $XX net the year, million $XX expect to the reflecting to we debt

XXX basis tax higher was quarter. point last The XXX XX.X% on a representing and during award due from to decline price associated basis XX%, the decrease equity in year. was compensation, from point impact second exercise stock-based and a levels rate activity tax quarter the second with stock benefit quarter The the excess resulting of

this favorable financial XX% lowering benefit, of XX.X%. a tax year XX% can to full the excise prior XX. our of revised be tax from XX% to on year full of guidance rate of summary for are found our slide outlook we our outlook As result a A range to

Accordingly, improve to respect revenue expect recovery, quarter, while the the third sequentially research confidence resume second already conversations year-over-year the a high growth rate demand quarter we organic the continue reported based mid- For their be activities. expect on with range client single-digit in to basis as we range. with and and revenue begun from have we to clients level, in to so to growth the to greater on the high do growth COVID-XX single-digit

compared of the when our we around of to growth of $X.XX. nature earnings that we in quarter our COVID-XX during future. current to their efforts and the our the continue thanks support extraordinary clients, to colleagues closing, to the the demonstrate of environment clients world pandemic, single-digit face work critical very last and research to results, employees, that fully by our with will In and both we per challenges continue we to we share year's level third our high do, communities shareholders. presented pleased efforts, and quarter the successfully second commitment the can and demonstrate expect the In are We the

We two-year set that the resumption target, including our the which last targets strategy, September, activity, XX% of and Thank high achieving revenue in single-digit well as and the you. financial operating our includes are operational as XXXX. margin continued of M&A we execution focused organic of growth on a

Todd Spencer

concludes The take questions. That now will operator your our comments.

Operator

first Thank to Instructions] go line And Tycho with Peterson you. [Operator of ahead. the Please JPMorgan. we'll go

Tycho Peterson

[Technical Jim, any Difficulty] Thanks. you give I'm the just bookings us wondering on rough if could guidance

James Foster

Tycho? cut out He totally on anyone Does me. hear,

Todd Spencer

he No, out. did cut

Tycho Peterson

You're Can hear Hey, you still us. me with Jim. now?

James Foster

Yes.

totally out so just You cut

Tycho Peterson

Okay.

that. just numbers and on any vaccine you about any Are The just me both the opportunity? able from around to let tailwinds, question the and put therapy So bookings anticipated sorry was work. for COVID COVID

James Foster

not that. be need to to overstate No. We careful

to be our number proud want to just delighted We participating. with to it. COVID material We're drive a to you going We're we're happy I of to So work that don't from work clients. have small that the significantly prioritize large think possible. as whenever that's financials.

Tycho Peterson

Okay. And then you're taking CapEx. up

You maybe of time, you're your faster recovery, the a talked about reiterating financial two-year increases same outsourcing, in kind yet targets. at

if tied the to trending dynamics. kind outsourcing? a higher increases to to direction to sounds getting the dynamics? And talk talk curious two potentially to incremental point It CapEx investments of So can where you're those you for can like just are right But in just in I'm the years. everything you is you guiding than the in those next maybe

James Foster

Yes. Go you, is ahead. David? mean I that

David Smith

Yes.

James Foster

ahead. Go

David Smith

I a kind Tycho, sort situation. to because we of conveying that normal just we're down last in the back to the CapEx COVID getting Well, a of was is brought say, quarter we're What going again. really of the actually position

and more it's XXXX capital up meet expect thinking can XXXX. we future, we in demands rebuilding sure those the and so about thinking that basically And demands the making about

James Foster

have basis work. impossible remarks, would to discovery, I that at board, our as and we in continuing though actually we my to to safety, David said, biologic, increasing capacity even prepared from just incremental be having multiple just And it's in capacity I we're businesses, it a down, on accommodate and sufficient multiple pretty time can sites across vigilant mean, much you when And mentioned clients. the diligent, add, I ensure to that took China, as about capacity, demand extremely get Tycho, the

to stay ahead we it. of So have

we spending strategically, knowing a very, business don't clients provide to we've good about for And last, almost essential cash, think done that the being very very that. job order very access but our and to our to decade I that know, do the services. doing in thoughtfully, careful I safeguard it's

Tycho Peterson

since should do last got to Okay. it. the meaningful? appetite teed up, Cellero Obviously, one you've maybe quickly, telegraphing just something are but deals? on Or highlighted M&A you And resumption activity one of you just we more assume an type similar

James Foster

is good about preliminarily, What I to year. balance we're quite anything the the feel that don't and, is to fact the next trying regard business the We year specifically impart good really of to think want about we with telegraph solid. scale.

there We a very there sizes. a very, cut always real I we It's had things that we're paused sort certainly QX. which speaking out time, fair and highly I very say field, are small critical we're to strategic our do. conversations, but and Cellero, activities. a very of But They we are as have be would few soon We that that a a wide than They are across number very variety nothing big. would modest-sized obviously, kind a pretty swath of of say of to would targets real deal. bigger do. of those which in resumed pleased

Tycho Peterson

Okay. Thank you.

James Foster

Sure.

Operator

And Eric line next, Please we'll with go Robert go the W. ahead. of to Coldwell Baird.

Eric Coldwell

Thanks very much.

research hoping First the question distinction to accounts get little more between is models biopharma accounts. a academic performance in versus and

academic would helpful. versus could on be sense you the some us pharma If in magnitude in give decline

James Foster

impact really of academic academics. pharmaceutical was some but the accounts. the And The some Eric, Sure. most sites closures was Yes, hit, had profound fast. were sites, big some of biotech we and closure closures

or buying closed use have with fast. sudden PPE-ed in feel are in aren't research models because when work academic the obviously, impact. there research the associated in which spec. I decoupled think the students, to with big, should this academic way they too setting, in of setting out where students, very didn't, going and animals being setting, sites And any are are retrospect, is done and case, risk activity the very and people they feel, grow we they people And the nobody's an to but labs so an

those more back were of we level. pretty all sort would they're levels, pulled high academic they making buying open. they the quickly anticipated it. we did back not provost to all plans anticipated We're saying, though lever And because to have, yet. a they pretty institutions folks. at We to talking had yes, open And had even sorry, stop return the so we open on than were they So we're get these slowly

of lot the June So of in the Europe a and quarter and China opening the in things U.S. middle for

pressure critical regardless So often have a pleased next with sort working positive given course, fact And diseases across don't of these ground-up isn't the again, the that. facilities, labs. would and particularly whole COVID. work that is or COVID whatever in they under do hoods, people the doing that with I in that of host are wave of anticipate they're often of

We prepared confident to We in for quite scaled open. that we're continue for will So animals. will They that. buy preparation they that. up to continue

they And work. service because right back able as quickly to to they pretty open get we're want being so the to clients

and So mostly pharma. academic very little

Eric Coldwell

Yes.

to to say, academic? was XX%, So your XX%, XX% safe decline of XX% due

James Foster

say I some and that off closures, very I would hand. was know yes. don't the was number But think academic so impact yes, significant secondarily I that much pharma

Eric Coldwell

one I on If more could enough. ask HemaCare. Fair

James Foster

Sure.

Eric Coldwell

the in might the levels? of there site about I'm of your worked of much you term. place the any that interest citizens on the back preserved increased think about that in now if reopen activity, that through Or quarter, dynamic I'm donor of so. I curious have you given short still had in up Has the have picked seeing with number are again. concerned during middle open? incidence number challenges it's still by moving notice and your or states sense then did that inventory the did looks just of what plans contingency quarter, in curious are how is business site the COVID. How what's a I'm California. you donor going you on frozen We to if forced close And

James Foster

lot know activity of importance looks And of good. a the donors There's first-rate we a it's well, that Yes. really and understand they repeat Donor facility. donating.

clinic with feel to accommodate made social to I So there. of donor think that. regard we've for accommodations safe Obviously, most within the distancing them

to we essential. And So to we there have plans, it Work's work. been had would open. hope continue that pretty we been would in keep to retrospect, might able able be better

site kept we So do during the parenthetically. in which that process just pandemic. able the would donor be their to of we're Cellero, open owning,

possible. So it's quite

that. pretty feel are about strong. we good Inventories So

we that event side. ship could have closure, well. from site product there's unlikely we frozen that think, I a the, in second as still another So And

on it at, business for going is years longer getting Obviously, for developed that this it. bought as had least improvements when or So we to growth we are and would are back are basis said year. next do that manufactured. rate the to the kind XX% business forward But we is at process a going grow five therapy of anticipate drugs and remarks, probably made won't this cell the in as anticipated it we prepared

we look So the tools business. critical drug forward provide bigger companies to a to footprint in having to these the able be to

Eric Coldwell

you, Thank Jim.

James Foster

Sure.

Operator

here with ahead. from John Please next Blair. Kreger William go comes question Our

John Kreger

broader bit that differ? Hi. can much. sticking talk base? this gaining about little concept, a from you very and Jim, more you a with capabilities just adding what Thanks deal? are HemaCare donor sort of you Or how Cellero Are other just

James Foster

So little above. it's a

development drug companies we're therapy just the scale, is investments So the rate companies. of which new cell and important those these adding rapid given just companies, minting nature growth in of by

want time, something two, helps types, about the one. to understand, That the quickly. get some a you did Because HemaCare, area. at close talk, California geographic more we so scale, than proximity, clients of client site I it's wanted really one Number about recall, in but which so And we're January, having they when in we the the So talking expansion. you that may cells in number to cell sleep bought Boston we company, better. can doing with only was John, be to the the

guys have the south, Boston in something greater these So area. in and the the in west

and disease-state and diseases the cells, cells immunocompromised orphan we have who immobilized have And So both clients cells. diseases. stem diseases, which immunocompromised patients more that, cells, scale. from some love we is they They have so love other with

capabilities some on added that to do would probably we had we basis. scientific greenfield have have So a

now. we So have that

expansion. important geographic have and have We overall capacity, we very

John Kreger

to heard curious, do would work the that of moving is a time on unprecedented some request And you within you that even reports programs? a sort clients And Excellent. follow-up, rates. the there from for I'm these work tox you we've is that accelerate forward of at are COVID way then getting lines?

James Foster

critically drugs to Yes. vaccines. therapeutics is the Particularly the much across the vaccines, critical. Obviously, We be and safety going the safety they of to safety is portfolio. our going pretty assessment work important the testing, thing be definitely profile have fast-track more most as these the

healthy have of So do a we book business.

be We doing can. out everything everything can do trying it. certainly to are and to space prioritize doing We've them we just take vice the and can ready we to ready generally pre-COVID, white it been lines to time with reporting the and quickly having more to to we client a versa. things everything we're regard we're data doing We're accept give but of when process

think I both because this so iterative there So on is sides process, the and process responsiveness to society. is communication really obviously important the

yes, with really we're pleased that proud role. and So

John Kreger

you. Thank Great.

Operator

Goldwasser come question ahead. next Please with from will go our Morgan Stanley. Ricky And here

Ricky Goldwasser

Hi, good morning.

of what levels? the on recapture? When long do margin. think to you when historical for do kind going it's margin do structure, how to take you to think to think the you about margin And return question you volumes see First

James Foster

you broke up So Ricky. at beginning, the

in Or being RMS you're So restored about margins specifically? talking

Ricky Goldwasser

And long think you In RMS, take? margins you how to historically? back do type do can go volume particularly. see for What need of to

James Foster

points the always to think at price. Europe unit don't up We the long all. mean, last few I Remember, I I years, points. couple in know, to couple a takes it percentage and percentage don't U.S. RMS down RMS a has volume been, of from in get of anywhere flat

for than is being the the literally need being so less more nothing or and take open. as this animals they they closed clients And research able not that to

business opening as instigated some ways, the only earlier. would We in COVID has world, strong services more stronger because been I strong, nicely, said they're but not it's So outsourcing. in the

ability are We important. want but build work, demand academic by to much being them the want to in of back closed now they provide pent-up a bit to right animals don't there's that, to And continue our opening. in I is capacity so as who China. little pent-up are as to get demand overstate institutions and

the we huge it's to kind last diminution let's say, I profit this quarter, historical some but possible event. of And build in it's would to don't be deliver revenue very quarters and because - obviously levels. mathematically bizarre back second a year third the barring imagine in think not So the towards nicely the in fourth it'll COVID-related year next did, year unforeseen fine, and margins of would continue that that I

Ricky Goldwasser

sourcing reducing and just reevaluating also Okay. And outsourcing we the next on one little you is Last mentioned actively dependency bit. spoke, on you're a supply strategy Asia. that time

opportunities the any there updates impacts for and in future? business So how the it

James Foster

we really And we good need done hard working at some our sources, ensuring we've historically. chain living think new, and a that many supply We're our do job very and have I variety critical from that they do to of Yes. they sufficient to were products where work. and work, from our some were where reduced historically inanimate in a increases from both tools

we really be about and year, feel So balance for of as this chain good very supply we'll for year the well well. prepared next

Ricky Goldwasser

you. Thank

James Foster

Sure.

Operator

we Please go can with to next, Brennan And of UBS. Dan ahead. line go the

Dan Brennan

sizing maybe planning in Thanks. that, missed are from standpoint to then I just reiterate extent trend there? the I'm the to Charles Great. improving given Could wondering, work the the on you Jim, kind River, a as there COVID out. base And you your what this was question quarter you related in how in call, of capacity look indicated the I think I whether continues. business, know maybe COVID just it. for we opportunity earlier a

James Foster

Yes.

work. It's that So to everyone's because prioritize a take time our We're in to large coming best going to and our doing best it from a to we're specific the what when give number. small we I process. have it doing We're get of We're said delighted clients. was the out rush. not

you, Just we that. helpful. just time it don't every like I'm to not do we'd just that's sure we speak and update things to have And

work. our of in have to not scheme beneficial So we're a be to the delighted financial but to be it's going results, the the It's going obviously number to huge cosmos.

beneficial. I think it's

to So want all we you that. don't read over

Dan Brennan

implies it, deceleration organic the in Got a it XQ. I it's while basis you're growth then year I an that impressive baking decent guide, it. you Is full math, conservatism do you're that just that And think if on think raising your in?

James Foster

to going to my Mr. I'm Smith, colleague, let respond that.

David Smith

Well, we draconian thought sensible here. scenario isn't when I say as wouldn't Remember, got puts takes. of spoke as isn't. it's we've last quarter. downside conservative, think there's The I a forecast be [indiscernible] a lot it it we might and

to So the we've building certainly the build up we same We taken that downside bit big normal for we've full passed beat the not to Remember, that. and back we're going level the get half table. QX, the we've as It's it had the for second over It's of up, QX, fall risk to increased that expect QX. is way but little a it's feel that revenue in a quite towards beginning getting QX. year. would from off in RMS very the

year," in the comments it's that So is think, of some Jim fully said too early, go "RMS to to earlier. I going to recover this to that

think we've to year protects the that of six COVID sensible headwind. go. still something We months us So got a again, for

of haven't We few assumed, we be our order will months sort in that there a worldwide complete forecast, a saw ago. stay-at-home

what COVID. of we've the with catching of So think on here of same And to but I'm therefore, on that's upside, time, at beat, on skis in some some we to get ahead front sense balanced, don't far and that's there's today. the get a our little bit got sort between trying uncertainties and something you sensibly passing I want too still get

Dan Brennan

And could in. Got it. if I one David, sneak more then

do be as math bit operating through of year just maybe the little full us you the what kind basis? triangulate back Just can expected in margins the on operating a and margin, like we in. walk on could on But look we range could a

David Smith

Yes.

was hesitated of expansion would range margin that year. So comments we've this a narrowing stage year. of color, margin of I've the could We, to some just have again, the XX%. at give What we've course. said you from we back last bit is I Last year that going made, from

is a year The margin, to first this year, of nice which of comparison done XX.X%. last XX.X% half we've

increase we had in despite So an that headwind the in research point heavy QX. XX basis models

first the has year up we've So gone of very well. half the

we're So with that. pleased

a get recovery some We the the improvement the get margin through promise. we're which as margins But as expect, until year. Manufacturing, won't Jim ago, it next models as is to mentioned, further historically. year. full in said moment can in mid-XXs, already the we You that we've we I a research same go won't had where

as were get DSA read wouldn't the into And in an more manufacturing. we in is share position, XXXX. expansion our So we've if I said your lion's I we'd always course, expansion much in go of of of where,

You've nice of DSA uptick in margins the of year, in seen year. a the even end the this last first half at

would So expect we see on some year-over-year improvement to continuing DSA.

Operator

we'll the Jefferies. next, go Windley with And Dave of to ahead. Please line go

Dave Windley

ways. development, question. light kind of development is River's of demand in opportunity Hi. this Charles should are have going Jim, the of Or the be come portfolio Thanks early vaccines? Charles vaccines COVID in that for a say, of River specific about, are developers category kind in your in my COVID guess, at those couple such opportunity of in services for thinking throughout taking But for the of on killer timing your is, position of the services early in for real they ones I people of life the heavy that XXXX? different

James Foster

both on to what vaccines, and said therapeutics that earlier, the in of I play, be. think I will think, we'll the an It's the role size safety the particularly predict the important impossible as I No, development side.

given biggest to no the of is There's necessity stakes. nobody current revenue. trying And dramatic is vaccine all happy high drug market our race just the in particularly, historical I I lot there's role that at of it's company sense provide certainly say the have a we're we're for the nobody and wouldn't think We're really like and critical. to So the data, it's to profiles But safety understands, the a to that you activity. what disease of time. give a a world now. a and tox given given wouldn't

corner, is to is, work some our hope a that think refined have drugs, think and role all think I to be that opportunity for it come the I since I here. a going is be line And to that while continue should may play even short-term though don't So vaccine we and critically there's increasingly down we important. the a more we significant around

Dave Windley

intellectual certainly there's an we between hope failure societal Yes, challenge a Great. and the about rates. for know what vaccine

about additional other my your a around theme outsourcing. kind throughout of comments question is So

it You in GEMS. mentioned

the my not to clients' maybe even also covered that. outsourcing been of of prompting there in kind other a DSA accessible. persistency question you terms mentioned But think in more as facilities where you when I in were of there's some readily and areas

shifts do you my the assess business. those so is, of question in the And how permanency clients your by various outsourcing of areas those

James Foster

by assess We it Dave, have everywhere. but we're it, seeing living it to

using shut GEMS. a earliest seeing seeing themselves, a River they good it Charles we're safety. they drugs with We're did plan them discovery, lot small very particularly discovery on depend begun of to and they the and side for and of or they have or client have large were somebody it on or down, in continuity So RMS they whether that couldn't and in didn't people depend develop couldn't then very, were they services, IS that had it's done a that business

For used the internally they again, and on depend couldn't safety some a of big clients, work did competitor or some ours them.

there's or either clinic microbial and into an to them it, contamination be test there's need course, from the manufacture be point of the a these biologics to Once Of it's of point view. going a to to view, testing huge need market. drugs increasing end-use they go from

for they going think And the And pleased us. it the benefit to think do is things got propensity or away utilizing quarter's we of I I or for I whatever I may and the And be why going situation's they very see the because soon. ones us, else. portfolio only think somebody stay with might be both the bring elongated. pricing for us it in longer our open." with and so may with use the space I they this to greater it internally is interesting the and and else Charles they're who, substantially time, when back over works then we'll they'll large with call, I be historically work back think anytime thought, utilize the opportunity think and work, are to is River they'll the I the said work, COVID to or have is speed decommission I who "Okay, be they'll to that think last their this quality frame now also bring very space house their them thinking, to very have clients I like the reason, would house? think something as and time like don't really So

we them better do do on And all better them some for on big themselves, say can can we just demonstrate were work, can can't that all depend proposition is even couldn't a to pharma, it. and do all value demonstrate and do we anything, the they business even don't is them of depending So because that they we continuity great is have live a this in. for depend geography proposition for is

we've and meaningful at it moment, of that to with we it gotten. or So pleased It's we're that but stick. will what continue. think that We what size the a really impossible the date predict think with will amount to transpired outsourcing pleased really business we're

Dave Windley

that. for I'll with you the answers. leave it Thank great. That's

James Foster

Sure.

Operator

of with next, Robert Goldman we'll Sachs. Jones line go ahead. And Please the go to

Jack Rogoff

to you Great. How in is Thanks question. margins. above impact. for you're seeing sustainable segment? you've in Solutions long-term the my guidance. This then is ask I the Support this taking the This for on row wanted you're throughout Microbial some fourth now facilities quarter Jack and at had time, that margins revenue your are about saw Rogoff that Bob. And Manufacturing or transfers that a

to margins trying just So you're understand how the are. that seeing sustainable

James Foster

want take David? that, You to

David Smith

rates often to are in out commented that been we years expand or seen, we continue some sort the signaled of called operating line. we needs get the than that moment remarks, to be continue mid-XXs. the rather mean top to I that business we ago you've preprepared We've Jim that In continuing we so Yes. the to to in up, invest growth we want as as margin are double-digit in the just capacity. drive on mid-XXs. plan can the want We've to we that biologics

increasing are So an not again, we line improvements the to that day, business business. some get well. the the of margins that end of where continue to continuing. we we But can at talk double-digit replow but to as we're back example making profit to today about that sure continue There microbial the have the process that's in in of some the of top into future, the been will invest make of growth prepared for sort to

Jack Rogoff

Makes sense. Thank you.

Operator

And next, line to of Bank can Avendano we go of go the Please ahead. with Juan America.

Juan Avendano

of quarter, the you. Thank My on the some Microbial to then like Hi. It was year. is delays due growth you there question seems first in were Manufacturing segment. COVID-XX this a Solutions in the Support also quarter before obviously, moderating in last even And that business installations. the one-timer noted

And the there. Solutions double-digit regain business question of Microbial this may low you confidence is able on leave it sustain have growth in to specifically? what I'll level my business, So and the that be do you

James Foster

Yes.

be comparisons into for clients been new of have out you the And question haven't this we massive big are that much the to no year-over-year client whack. lot and And and phrased the that pretty causes lower able the the a causing them. to you directly are quarter. a a think with identified areas yes, and well. impacts. It's We the preorder issues COVID I had install growth, of that systems, to get and Juan, So RMS demand growth the we

of sell slowly. Celsius installed What open of if go remotely, system a and it's said in clients We've we've that second that and able let's them, systems. year stick loosen systems. in them to reagents going cartridges some and I that it, this we to number remarks, happens and and surprising. Clients let's the the is it's one say were systems or increase. walk some through beginning up up. the say, This Endosafe amount with associated to been prepared them my As associated to beginning may are quarter, along is in not even need But an which

have along just So go as the don't the we we have that equipment, sell to well. So razor hit right? blade with we it,

entirely clients clients want Celsius world to confident bacterial with the the very which in install business, that contamination, that, COVID are much when back particularly then can should systems we the the some we're we and having open, systems, clients continuing our get competition, like, an faster. So systems. because from answer double-digit they more sophisticated much technology clients to by convert share convert by We're competition's the from low-digit to own get conventional ours levels. having take of methodologies And continuing we're to to

an air odd sort pocket people that I'm you the to because see it's we really business. happy asked Juan. So the question want here, of And through

is manufacturing not reason are XX% as the process going is manufacturing the David's, prepared in the over in But of As because microbial in the we that margins margins. give we the margin to we said, better my of and made because remarks you said we're exact part process. in improvements

think, to that efficiency in drive So business. line a going top in we to, forward, addition robust more continue I

margin. So River it's very to nicely Charles operating contributing total

Juan Avendano

you. Thank

James Foster

Sure.

Operator

go line go next, Donnelly we Please of with And can Citi. Patrick ahead. the to

Patrick Donnelly

were drug one integrated how seeing the there? [indiscernible] delays. you. the area out sounds you on Jim, complex normalize maybe side, small the and It saw an you called just quickly quarter, tone things general in Thanks. biotechs, for Last you like discovery projects some discovery normal some

James Foster

Okay.

think got You I cut out, I but question. the

didn't had it think or to work a had impact other companies access have impact COVID know going just ability because that's paused. we they companies’ up be don't their while the we're integrated if had a those So some I others, be biotech reinstituted clients, done, pretty were those. kind hit of one. them to couple how number And that projects they complex, to to considering back with good I paused slack. really of pick pharma conservative." ones pause we they the or we very and studies, have necessarily "Well, And So of multiyear, capital conservative, those place Number small think a thought, us, pulled few and two, biotech would clients their when expensive and they get

some of think terms terms they're and complex I the kind drug These terms them to and everyone's we that the solve that have, figured big complex of problems are really are means solve complex really really discovery can them out clients. impact the hopefully, doing problems. So what helping in studies some development work somehow help in the integrated mysteries COVID of of in processes, to

one be. business sort will that second continue a important right of quickly our will part that increasingly move to the quarter, but the It's from one later that So of an be us distinguishes competition. relatively we to business continue in not think and and through huge

Patrick Donnelly

Thanks. Helpful.

James Foster

Sure.

Operator

we to go of with Please Evercore Vijay the And go line next, Kumar can ISI. ahead.

Vijay Kumar

some target. question. perhaps singles, why my on snapping the roll on top the XX% for what the comments XXXX. high up. we back target drives see perhaps doubles? well I'm that into new XX% in versus extending into context margin put expansion ones. margins, Thanks a XXXX at taking wouldn't comments them step-up us. relative the for second, into organic, for RMS of I'll to on quick some made you around I a normal single And high low singles margin reiteration One, the XXXX, for the curious, Maybe here, had two perhaps implies big Curious touching LRP line, the question. a even Jim, step

James Foster

premature high to been will can vagaries has about specifically, ourselves to RMS the deliver single-digit we ahead don't do next We right and if our mean, margin I We articulated numbers be given but better, in revenue target be we performing just you to be obviously that. very just So And we're fact always mid-single-digit your of way would better to have want all and well meet just would the everything we world grower. than pleased that low notwithstanding be comments were do it RMS. of would the to get our now, operating we here. very hope year XX%. growth pleased,

the I saw somewhat businesses rate. those larger the gets you therapy ready to as And think I growing don't the to COVID. will the XX%, to and cell was a not to mid, them growth we're product HemaCare that's just in directing. But With impacted articulate We at rate second math you're growth directionally, going stimulate where by that. hopefully, we to but perform. businesses, bought exceed quarter, we low want think

higher. those them So push always hit to targets. delighted We're to we'd be driving

current better. So time. I'm impossible they I'm be something that the to that's saying just that guide willing not not saying it's at could to we're

Vijay Kumar

helpful. that's And And...

David Smith

your signaling one-off XXXX, take math a to we're But comps for still research I low we do when XXXX to your going in get way models point point models a because base base then to about is the comps. what I normal to still year-over-year COVID year-over-year would XXXX, for XXXX. get get that we closer XXXX. point, long of I sorry. low an research growth. you yes, get back structure the and benefit had If we way start year-over-year from working in a we'll see that XXXX. about a it's to Jim's compared in organic But But of seeing a

Vijay Kumar

Understood. you, Thank guys.

Operator

Please ahead. we'll Stephen go with Baxter And the Wolfe go to next, of line Research.

Stephen Baxter

the wanted have you deal question environment. you about talk how to in little about you're traveling, announcing Hopefully, you're acquisitions bit I when, current bigger for deal think about do? ask Obviously, integrate be you to to thing in would any the Or is difficult deals? larger Hi, can And the people me, for to you process of in a hear couple quarters a next today. the integration thanks Can obviously, rate-limiting ability you a a question. you a for is a over factor the environment? picture able current doing way integrate example, okay. as handling ask to the larger

James Foster

question. That's a good

We have large a pretty sophisticated integration team.

of is to stuff, the and majority has the to do to the think of somebody the we extent involved, go the of ability any be Facility have our vast we to I much the not remotely. system so obviously, problem. back-office get integration there, stuff Certainly, issues, And that will. a can integration, done all

We have local people.

we we point the educate although of companies to en remotely, So seen who et we're a masse. organizations we from view, that can sales we've can facilities help by I we and think video, sales buy buying, do do cetera. didn't Ability

doing us small. no, deals, a it strike that, that's or large doesn't headwind So

something to get that sit prolonged, to think be at. I really COVID going increasingly one, of going for better able there's things business. change size be not We just on It for doesn't situation our with And I, we've wait matter the deal. and hesitant opportunities. we're wouldn't will got think be and to some the be and integration is the to to

strong So sheet. balance we have

of of the key lot that We've the competitive a enhancing have our We is adding River differentiator targets. seen between Charles all and and competitors. portfolio

And that. So There to have are do we advance continue able and want out there. we targets to deals. to team ready, willing a additional

So I fine. be just them we'll to integrate think able

Todd Spencer

us joining the are everyone you. Thank to conference questions, conferences All right. conference If thank this look in to I'd no speaking morning. during investor call further concludes forward the September. on several This upcoming you there We like with call. for

Operator

you Thanks does call very that today. AT&T participation Ladies for for Thank and conclude Teleconference. the much. your for gentlemen, using

disconnect. You now may